Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > See “Risk Factors”.

<< Previous

Bullboard Posts

Next >>

Comment by mmayeron Aug 09, 2018 9:40am

47 Views

Post# 28432584

RE:See “Risk Factors”.

You forgot to mention how cosmic rays may erode the sp.
you also forgot the risk if an atomic bomb or an alien invasion!

come on... get with the program!

allain250 wrote:
There is currently no market through which these securities, other than our

Common Shares, may be sold and purchasers may not be able to resell such securities purchased under this short form

prospectus. This may affect the pricing of our securities, other than our Common Shares, in the secondary market, the

transparency and availability of trading prices, the liquidity of these securities and the extent of issuer regulation. See “Risk

Factors”.